Skip to content

Bioavailability and Vascular Effects of Apple Polyphenols

Bioavailability and Vascular Effects of Apple Polyphenols

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01097226
Acronym
POLYMALUS
Enrollment
12
Registered
2010-04-01
Start date
2010-04-30
Completion date
2011-06-30
Last updated
2013-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Dietary intervention, bioavailability, Healthy volunteers

Brief summary

The main purpose of this study is to determine the oral bioavailability of flavanols (polyphenolic compounds) from apple granules and an apple extract delivered in a water based beverage at two different doses. We will also investigate the effects of apple flavanols on nitric oxide production.

Detailed description

This study is a randomized four phase crossover trial investigating the bioavailability of apple flavanols and the effects on nitric oxide products, a surrogate marker for changes in endothelial function. Each test phase will comprise a 3 day period of intervention which will be identical in nature (except for the test product consumed) and separated by a minimum of 1 week. On days 1-3 of each test phase volunteers will consume a low flavanol diet. After consumption of the test product on the morning of day 2, blood and urine samples will be collected at regular intervals for the next 24h.

Interventions

OTHERApple extract delivering 70 mg epicatechin

Delivered as a flavoured water based beverage

OTHERApple extract delivering 140 mg epicatechin

Delivered as a flavoured water based beverage

OTHERApple granules delivering 70 mg epicatechin

Delivered as a puree

OTHERWater delivering no epicatechin

Delivered as flavoured water

Sponsors

Danisco
CollaboratorINDUSTRY
Coressence LTD
CollaboratorUNKNOWN
Quadram Institute Bioscience
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
45 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Men and women aged 45-70 years

Exclusion criteria

* Smokers (or have quit smoking less than 1 year ago) * Regular prescribed medication (excluding some eye and skin medication that is judged not to affect study outcome) * Non-prescribed medication that may affect the study data, e.g. aspirin. The use of non prescribed medications will be assessed on an individual basis. * Dietary supplements or herbal remedies which may affect the study data unless the volunteer is willing to discontinue them for 1 month prior to starting study. (Please note that some supplements may not affect the study and this will be assessed on an individual basis). * Gastro-intestinal diseases (excluding hiatus hernia unless symptomatic or study intervention/procedure is contra-indicated). * Diabetics * Known cardiovascular disease * Asthmatics (unless no medication taken for 1 year) * Lactose Intolerance * Pregnancy or have been pregnant within the last 12 months * Parallel participation in another research project which involves dietary intervention * Participation in another research project which has involved blood sampling within the last four months unless the total amount of combined blood from both studies does not exceed 470 mls. * Has donated or intends to donate blood within 16 weeks prior to or during the study period. * Depressed or elevated blood pressure measurements (\<90/50 or 95/55 if symptomatic or \>160/100) * Any person related to or living with any member of the study team * Results of the clinical screening which indicate or are judged by the HNU Medical Advisor to be indicative of a health problem which could compromise the well-being of the volunteer if they participated or which could affect the study data. * Alcohol consumption \> approximately 20 g alcohol/day (2.5 units/day) * BMI \<19.5 or \> 35

Design outcomes

Primary

MeasureTime frame
Area under the plasma pharmacokinetic curve for total epicatechin24 hours

Secondary

MeasureTime frame
Additional measures of bioavailability: Plasma Cmax, Tmax, half life and urinary excretion24 hours
Changes in levels of nitric Oxide metabolites as a surrogate measure of endothelial function after consumption of apple flavanols24 hours

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026